- Bio-Rad is clearly the future choice in digital PCR, winning easily over nearest competitors
MOUNTAIN VIEW, California, March 12, 2013 /PRNewswire/ -- Based on Frost & Sullivan's independent research, 2012 Quantitative and Digital PCR Instrumentation and Consumables Purchasing Trends, Bio-Rad's QX100 Droplet Digital PCR emerged as the future leader in the digital polymerase chain reaction (dPCR) market segment among healthcare-related laboratory decision-makers in North America.
With digital PCR emerging as an exciting technology that is generating much attention in the industry for its precision, reproducibility, and promising potential in diagnostic and pharmaceutical applications, Bio-Rad is uniquely positioned to gain the strongest market share. Its QX100 Droplet Digital PCR system is the most popular dPCR platform on the market, with 56 percent planning to use it in 2013.
"The high sensitivity of dPCR makes it ideal for a growing number of applications, including copy number variation, rare mutation detection, and absolute quantification of nucleic acid sequences," said Frost & Sullivan Research Analyst Karolina Olszewska. "In this high-growth, promising market, Bio-Rad's investment in digital PCR will prove fruitful."
As the industry develops new applications for the technology, making it more valuable to the user, adoption rates are expected to increase. In fact, Frost & Sullivan expects the dPCR instrumentation market to grow at a tremendous compound annual growth rate of 52 percent from 2011 to 2016.
"Our survey indicates that Bio-Rad will be a definite future leader in the dPCR market segment," said Olszewska. "Over half of those who plan to install dPCR in the next 12 months intend to choose the Bio-Rad QX100 Droplet Digital PCR system."
What sets the QX100 Droplet Digital PCR System apart from other dPCR platforms on the market is its precision, simple workflow, affordability, and easy integration into the laboratory. With a market-leading platform and a strong reputation among researchers, Bio-Rad is poised for success in the cutting-edge dPCR market, and is the ideal recipient of the 2012 North America Laboratory Researchers' Choice: Future Market Leader of Digital PCR Technology.
Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in one or more aspects of its operations. The award recipient has distinguished itself through its proactive strategies that position it as an industry leader. More specifically, award recipients are determined directly by survey respondents' responses based upon their perceptions of the companies competing in a particular market segment.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
SOURCE Frost & Sullivan